Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29)

Autor:	Dieter Koeberle, Piercarlo Saletti, Markus Peck-Radosavljevic, Panagiotis Samaras, Anna Dorothea Wagner, György Bodoky, Jean-François Dufour, Britta Tschanz, Michael Montemurro, Gabor Lakatos, Michael Buehlmann, Arnaud Roth, Qiyu Li, Jonas Feilchenfeld, Ivana Cvijetic, Daniel Rauch, Gyula Demeter, Karin Ribi, Daniel Horber
Rok vydání:	2014
Předmět:	SASL Sorafenib Oncology Cancer Research medicine.medical_specialty Standard of care Everolimus business.industry medicine.drug_class medicine.disease digestive system diseases Tyrosine-kinase inhibitor Internal medicine Hepatocellular carcinoma Medicine In patient business neoplasms computer computer.programming_language medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:4099-4099
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.4099
Popis:	4099 Background: Sorafenib (S), a multitargeted tyrosine kinase inhibitor, has become standard of care for first-line systemic treatment of advanced HCC. Everolimus (E) is a potent inhibitor of the...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6ced62b637ba59612775b98b6d793da7 https://doi.org/10.1200/jco.2014.32.15_suppl.4099 Zobrazit plný text záznamu